Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1646289 | 0.93 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL27326103 | 0.80 | ACHE (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3015868 | 0.80 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL774178 | 0.80 | ACHE (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL27326106 | 0.80 | ACHE (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30621167 | 0.77 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL27994173 | 0.76 | CA1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30341051 | 0.75 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13154399 | 0.75 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30003091 | 0.74 | CA1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| CN-110072864-A | TDO2 INHIBITORS | 基因泰克公司 | 2019-07-30 | — | — | CN | claimed |
| US-20260078114-A1 | COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF | TYK MEDICINES INC (CN) | 2026-03-19 | — | — | US | disclosed |
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-09-02 | — | — | US | disclosed |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20220324872-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-20220315619-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-10-06 | — | — | US | disclosed |
| US-7829665-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2103623-A2 | Novel macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1924594-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1797070-A1 | COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATIONS THEREOF AND USES THEREOF II | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2007015824-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006033633-A1 | COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATIONS THEREOF AND USES THEREOF II | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | PSEN1 3943/4885PSEN2 4118/4885APH1B 2775/4885 |
| US-20220324872-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | PSEN1 2617/4885PSEN2 2307/4885APH1B 1392/4885 |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | PSEN1 3943/4885PSEN2 4118/4885APH1B 2775/4885 |
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | PSEN1 4219/4885PSEN2 4161/4885APH1B 2757/4885 |
| US-20260078114-A1 | COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF | CDK4, CDK1, CDK3 | PSEN1 2080/4885PSEN2 2125/4885APH1B 3276/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | PSEN1 4219/4885PSEN2 4161/4885APH1B 2757/4885 |
| US-20220315619-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | PSEN1 3889/4885PSEN2 3838/4885APH1B 554/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | PSEN1 3943/4885PSEN2 4118/4885APH1B 2775/4885 |
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | PSEN1 3889/4885PSEN2 3838/4885APH1B 554/4885 |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HCCS | PSEN1 4366/4885PSEN2 4369/4885APH1B 2732/4885 |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | PSEN1 3943/4885PSEN2 4118/4885APH1B 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.